Hemispherx Biopharma Hires New President/Chief Operating Officer to Lead the Company's Drive to Commercialization.

PHILADELPHIA -- Hemispherx Biopharma, Inc. (AMEX: HEB) announced that it has hired Anthony A. Bonelli as President and Chief Operating Officer. Mr. Bonelli is leaving his position as president of Anthony Bonelli Associates, Inc., a healthcare consulting and advisory firm whose clients include major multinational pharmaceuticals, biotech, managed care and investment banking firms.

From 1995 to 1998, Mr. Bonelli was President and COO of Neuman Health Services, which Forbes Magazine ranked as the number one privately held U.S. healthcare/drug company. Prior to that, he was President of Health Economics Research, a consultancy, and from 1993 to 1994, he was President and COO of Copely Pharmaceuticals. As Vice President, Institutional Health Care SBU of Warner-Lambert's Parke-Davis Group from 1987 to 1993, he reported to the President, Parke-Davis North America, establishing an autonomous organization within the Parke-Davis Group with sales of over $500 million.

Mr. Bonelli is a graduate of Harvard University with a Bachelor of Science in Biological Sciences and holds an MBA from Rutgers University Graduate School of Business and a JD from the University of San Francisco School Of Law.

Mr. Bonelli has over twenty-five years of diversified healthcare industry experience. Most recently, he served as President and CEO of Optigenex, an applied DNA sciences company, since October 2005, having joined that company in September 2004 as President and Chief Operating Officer. As principal of Anthony Bonelli Associates between 1999 and 2004, some of the firms he has advised include Parke-Davis, Schering-Plough Company, Aventis, Pharmacia and Pfizer. From 1998 to 1999, he was President and COO of Vitaquest International, a custom developer and manufacturer of vitamins and nutritional supplements.

Dr. William A. Carter, Chairman and CEO of Hemispherx Biopharama, Inc., commented, "Mr. Bonelli's experience and expertise greatly strengthen our ability to deliver Hemispherx into commercialization and profitability. His experience and knowledge of marketing, specialty pharma, management and business development will help us formulate the strategies necessary to extract the underdeveloped value from our approved natural human interferon Alferon N Injection[R] and our experimental therapeutic Ampligen[R], for which we will soon be filing an NDA for Chronic Fatigue Syndrome."

Chronic Fatigue Syndrome has recently secured recognition as a highly debilitating disease, a disease that is now acknowledged to be far more debilitating and far-reaching than was previously acknowledged. The CDC in recently published studies and a public awareness campaign has presented Chronic Fatigue Syndrome (CFS) as a disease more debilitating than Multiple Sclerosis (MS), potentially affecting more than four million people in the United States alone (reference: the CDC web site at http://www.cdc.gov/cfs/PSAs.htm).

Mr. Bonelli is replacing Doug Hulse, who has been serving part-time as President and COO of Hemispherx. Mr. Hulse had been contracted to Hemispherx from The Sage Group. Mr. Hulse's various responsibilities to The Sage Group have grown to preclude him from dedicating his time fully to Hemispherx. Mr. Hulse has been essential to Hemispherx's success in expanding its manufacturing capabilities and intends to continue with the Company in a capacity of Senior Advisor to the Hemispherx Chairman and Board of Directors.

About Hemispherx Biopharma

Hemispherx Biopharma, Inc. is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection[R] and the experimental therapeutics Ampligen[R] and Oragens[R]. Alferon N Injection[R] is approved for a category of STD infection, and Ampligen[R] and Oragens[R] represent experimental RNA nucleic acids being developed for globally important viral diseases and disorders of the immune system. Hemispherx's platform technology includes large and small agent components for potential treatment of various severely debilitating and life threatening diseases. Hemispherx has in excess of 100 patents comprising its core intellectual property estate, a fully commercialized product (Alferon N Injection[R]) and GMP certified manufacturing facilities for its novel pharma products. For more information please visit www.hemispherx.net

Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the Company (including Ampligen[R], Alferon LDO and Oragens) are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Clinical trials for other potential indications of the approved biologic Alferon N Injection[R] do not imply that the product will ever be specifically approved commercially for these other treatment indications.